Mas Sergi, Blázquez Ana, Rodríguez Natalia, Boloc Daniel, Lafuente Amalia, Arnaiz Joan A, Lázaro Luisa, Gassó Patricia
Departments of aPathological Anatomy, Pharmacology and Microbiology bPsychiatry and Clinical Psychobiology, University of Barcelona cDepartment of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences dDepartment of Clinical Pharmacology, Hospital Clinic de Barcelona eAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona fMental Health Networking Biomedical Research Centre (CIBERSAM), Madrid, Spain.
Pharmacogenet Genomics. 2016 Nov;26(11):487-496. doi: 10.1097/FPC.0000000000000240.
Pharmacogenetic studies of fluoxetine in children and adolescents are scarce. After reporting the effect of genetic variants in genes related to the fluoxetine pharmacokinetics on clinical response in a pediatric population, we now evaluate the impact of genetic markers involved in its pharmacodynamics.
The assessment was performed in 83 patients after 12 weeks of fluoxetine treatment. The genetic association analysis included a total of 316 validated single nucleotide polymorphisms in 45 candidate genes involved in six different pathways.
Clinical improvement after treatment with fluoxetine in our pediatric population was associated significantly with two polymorphisms located in genes related to the serotonergic system: the 5-hydroxytryptamine receptor 1B (HTR1B) and the tryptophan 5-hydroxylase 2 (TPH2).
Although a wide range of candidate genes related to different pathways were assessed, the results show that genetic markers directly related to serotonin have an important effect on fluoxetine response.
